114 related articles for article (PubMed ID: 18343512)
1. Exploring the role of BRCA1, BRCA2 and RAD51 as biomarkers for breast cancer.
Ziogas D; Liakakos T; Lykoudis E; Fatourou E; Roukos DH
Radiother Oncol; 2009 Jan; 90(1):161-2. PubMed ID: 18343512
[No Abstract] [Full Text] [Related]
2. Dinucleotide repeat polymorphisms of RAD51, BRCA1, BRCA2 gene regions in breast cancer.
Nowacka-Zawisza M; Brys M; Romanowicz-Makowska H; Kulig A; Krajewska WM
Pathol Int; 2008 May; 58(5):275-81. PubMed ID: 18429825
[TBL] [Abstract][Full Text] [Related]
3. Detection of loss of heterozygosity at RAD51, RAD52, RAD54 and BRCA1 and BRCA2 loci in breast cancer: pathological correlations.
Gonzalez R; Silva JM; Dominguez G; Garcia JM; Martinez G; Vargas J; Provencio M; España P; Bonilla F
Br J Cancer; 1999 Oct; 81(3):503-9. PubMed ID: 10507777
[TBL] [Abstract][Full Text] [Related]
4. Treating the genetic make-up of breast cancer: a new fashion?
Linn SC; Jonkers J
Expert Rev Anticancer Ther; 2007 Aug; 7(8):1065-7. PubMed ID: 17725409
[No Abstract] [Full Text] [Related]
5. Analysis of RAD51 polymorphism and BRCA1 mutations in Polish women with breast cancer.
Romanowicz-Makowska H; Smolarz B; Zadrozny M; Kulig A
Exp Oncol; 2006 Jun; 28(2):156-9. PubMed ID: 16837909
[TBL] [Abstract][Full Text] [Related]
6. The BRCA1/BRCA2/Rad51 complex is a prognostic and predictive factor in early breast cancer.
Söderlund K; Skoog L; Fornander T; Askmalm MS
Radiother Oncol; 2007 Sep; 84(3):242-51. PubMed ID: 17707537
[TBL] [Abstract][Full Text] [Related]
7. Increased expression of BRCA2 and RAD51 in lymph node metastases of canine mammary adenocarcinomas.
Klopfleisch R; Gruber AD
Vet Pathol; 2009 May; 46(3):416-22. PubMed ID: 19176491
[TBL] [Abstract][Full Text] [Related]
8. Association of BRCA1, BRCA2, RAD51, and HER2 gene polymorphisms with the breast cancer risk in the Bangladeshi population.
Parvin S; Islam MS; Al-Mamun MM; Islam MS; Ahmed MU; Kabir ER; Hasnat A
Breast Cancer; 2017 Mar; 24(2):229-237. PubMed ID: 27068824
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of BRCA1 and BRCA2 mutations in triple negative breast cancer.
Evans DG; Howell A; Ward D; Lalloo F; Jones JL; Eccles DM
J Med Genet; 2011 Aug; 48(8):520-2. PubMed ID: 21653198
[No Abstract] [Full Text] [Related]
10. Beyond BRCA1/2: polygenic, 'polyfunctional' molecular circuitry model to predict breast cancer risk.
Lianos GD; Zoras O; Roukos DH
Biomark Med; 2013 Oct; 7(5):675-8. PubMed ID: 24044557
[No Abstract] [Full Text] [Related]
11. Clinically relevant biology of hereditary breast cancer.
Foulkes WD
Semin Oncol; 2007 Oct; 34(5):379-83. PubMed ID: 17920891
[TBL] [Abstract][Full Text] [Related]
12. BRCA1/2-associated and sporadic breast cancers: fellow travelers or not?
Garber JE
Cancer Prev Res (Phila); 2009 Feb; 2(2):100-3. PubMed ID: 19174575
[No Abstract] [Full Text] [Related]
13. RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies.
Antoniou AC; Sinilnikova OM; Simard J; Léoné M; Dumont M; Neuhausen SL; Struewing JP; Stoppa-Lyonnet D; Barjhoux L; Hughes DJ; Coupier I; Belotti M; Lasset C; Bonadona V; Bignon YJ; ; Rebbeck TR; Wagner T; Lynch HT; Domchek SM; Nathanson KL; Garber JE; Weitzel J; Narod SA; Tomlinson G; Olopade OI; Godwin A; Isaacs C; Jakubowska A; Lubinski J; Gronwald J; Górski B; Byrski T; Huzarski T; Peock S; Cook M; Baynes C; Murray A; Rogers M; Daly PA; Dorkins H; ; Schmutzler RK; Versmold B; Engel C; Meindl A; Arnold N; Niederacher D; Deissler H; ; Spurdle AB; Chen X; Waddell N; Cloonan N; ; Kirchhoff T; Offit K; Friedman E; Kaufmann B; Laitman Y; Galore G; Rennert G; Lejbkowicz F; Raskin L; Andrulis IL; Ilyushik E; Ozcelik H; Devilee P; Vreeswijk MP; Greene MH; Prindiville SA; Osorio A; Benitez J; Zikan M; Szabo CI; Kilpivaara O; Nevanlinna H; Hamann U; Durocher F; Arason A; Couch FJ; Easton DF; Chenevix-Trench G;
Am J Hum Genet; 2007 Dec; 81(6):1186-200. PubMed ID: 17999359
[TBL] [Abstract][Full Text] [Related]
14. [Familial breast cancer genes].
Chiba N; Ishioka C
Nihon Rinsho; 2007 Jun; 65 Suppl 6():601-5. PubMed ID: 17682216
[No Abstract] [Full Text] [Related]
15. BRCA2, purified, reveals some of its secrets.
Schmidt C
J Natl Cancer Inst; 2010 Oct; 102(20):1529-31. PubMed ID: 20935268
[No Abstract] [Full Text] [Related]
16. The molecular pathology of hereditary breast cancer.
Palacios J; Robles-Frías MJ; Castilla MA; López-García MA; Benítez J
Pathobiology; 2008; 75(2):85-94. PubMed ID: 18544963
[TBL] [Abstract][Full Text] [Related]
17. Loss of heterozygosity in the RAD51 and BRCA2 regions in breast cancer.
Nowacka-Zawisza M; Bryś M; Romanowicz-Makowska H; Kulig A; Krajewska WM
Cancer Detect Prev; 2008; 32(2):144-8. PubMed ID: 18632222
[TBL] [Abstract][Full Text] [Related]
18. [Present conditions and the prospects for biomarker measurement in breast cancer].
Kawamoto H; Fukuda M
Nihon Rinsho; 2007 Jun; 65 Suppl 6():281-4. PubMed ID: 17679203
[No Abstract] [Full Text] [Related]
19. PIK3CA mutations and BRCA1 expression in breast cancer: potential biomarkers for chemoresistance.
Santarpia M; Altavilla G; Margeli M; Cirauqui B; Mesiti M; Cavallari V; Ramirez JL; Sanchez-Ronco M; Santarpia L; Taron M; Rosell R
Cancer Invest; 2008 Dec; 26(10):1044-51. PubMed ID: 18798071
[TBL] [Abstract][Full Text] [Related]
20. The roles of BRCA1 and BRCA2 in the cellular response to ionizing radiation.
Powell SN
Radiat Res; 2005 Jun; 163(6):699-700. PubMed ID: 16044500
[No Abstract] [Full Text] [Related]
[Next] [New Search]
